Poly(ADP-ribose) polymerase inhibitors: A novel drug class with a promising future

Cancer Journal

Volumn 16, Issue 2, 2010, Pages 83-90

  Gartner, Elaina M ^a   Burger, Angelika M ^a   LoRusso, Patricia M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

ABT 888; AG014699; BRCA1 gene; BRCA2 gene; BSI 201; INO 1001; Olaparib cpd; Poly(ADP ribose); Poly(ADP ribose) polymerases; Synthetic lethality

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 3 AMINOBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BSI 201; CARBOPLATIN; CEP 6800; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GEMCITABINE; GPI 15427; INO 1001; IRINOTECAN; KU 0058684; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PEMETREXED; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADJUVANT THERAPY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CHEMOSENSITIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; COLON CARCINOMA; DNA DAMAGE; DNA REPAIR; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; EXCISION REPAIR; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PAIN; PERITONEUM CANCER; PHLEBITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; QT PROLONGATION; RADIOSENSITIZATION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; TASTE DISORDER; THROMBOCYTOPENIA; UTERINE TUBE TUMOR; UTERUS CARCINOMA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77951445939     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181d78223     Document Type: Review

References (63)

1. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
2. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27:2705-2711.
3. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADPribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14:7917-7923.
4. Seimiya H, Muramatsu Y, Ohishi T, et al. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 2005;7:25-37. (Pubitemid 40126380)
5. Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13:3046-3082.
6. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: 'PARlaying' NAD into a nuclear signal. Genes Dev. 2005;19:1951-1967.
7. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963;11:39-43.
8. D'Amours D, Desnoyers S, D'Silva I, et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342(Pt 2):249-268. (Pubitemid 29425344)
9. Kraus WL, Lis JT. PARP goes transcription. Cell. 2003;113:677-683.
10. Tomoda T, Kurashige T, Moriki T, et al. Enhanced expression of poly(ADPribose) synthetase gene in malignant lymphoma. Am J Hematol. 1991;37: 223-227.
11. Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphateribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:338-344. (Pubitemid 32374852)
12. Fukushima M, Kuzuya K, Ota K, et al. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett. 1981;14: 227-236. (Pubitemid 12223479)
13. Alderson T. New targets for cancer chemotherapy-poly(ADP-ribosylation) processing and polyisoprene metabolism. Biol Rev Camb Philos Soc. 1990; 65:623-641. (Pubitemid 20377686)
14. Wielckens K, Garbrecht M, Kittler M, et al. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem. 1980;104:279-287. (Pubitemid 10099524)
15. Berger NA, Adams JW, Sikorski GW, et al. Synthesis of DNA and poly(adenosine diphosphate ribose) in normal and chronic lymphocytic leukemia lymphocytes. J Clin Invest. 1978;62:111-118.
16. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphateribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 1983;43:3441-3446. (Pubitemid 13061611)
17. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res. 2000;460:1-15. (Pubitemid 30365046)
18. Masutani M, Nozaki T, Nakamoto K, et al. The response of Parp knockout mice against DNA damaging agents. Mutat Res. 2000;462:159-166. (Pubitemid 30190223)
19. Ame JC, Rolli V, Schreiber V, et al. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem. 1999;274: 17860-17868. (Pubitemid 129519145)
20. Menissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003;22:2255-2263.
21. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res. 2003;9:5370-5379.
22. Rosell R, Jassem E, Skrzypski M, et al. Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemo-naive nonsmall cell lung cancer (NSCLC) patients (p). ASCO Annual Meeting Proceedings. 2007;25(18S):Abstract 7551.
23. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5:689-698.
24. Liu L, Taverna P, Whitacre CM, et al. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999;5:2908-2917.
25. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421-440.
26. Iglehart JD, Silver DP. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med. 2009;361:189-191.
27. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005;11:6212-6217.
28. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
29. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434: 913-917.
30. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96:56-67.
31. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6:945-956.
32. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADPribose) polymerase inhibitor. Mol Cancer Ther. 2003;2:371-382.
33. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly- (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728-2737.
34. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13:3033-3042.
35. Penning TD, Zhu GD, Gandhi VB, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimid- azole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009;52:514-523.
36. Tentori L, Leonetti C, Scarsella M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/ temozolomide efficacy against colon carcinoma. FASEB J. 2006;20: 1709-1711.
37. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4- Cyclopropanecarbonylpiperazine- 1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008; 51:6581-6591.
38. McCabe N, Cerone MA, Ohishi T, et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene. 2009;28:1465-1470.
39. Plummer ER, Middleton MR, Jones C, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res. 2005;11:3402-3409.
40. Olive PL, Chan AP, Cu CS. Comparison between the DNA precipitation and alkali unwinding assays for detecting DNA strand breaks and cross-links. Cancer Res. 1988;48:6444-6449.
41. Liu X, Palma J, Kinders R, et al. An enzyme-linked immunosorbent poly- (ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem. 2008;381:240-247.
42. Kunzmann A, Liu D, Annett K, et al. Flow-cytometric assessment of cellular poly(ADP-ribosyl)ation capacity in peripheral blood lymphocytes. Immun Ageing. 2006;3:8.
43. Morrow DA, Brickman CM, Murphy SA, et al. A randomized, placebocontrolled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis. 2009;27:359-364.
44. Dickey JS, Redon CE, Nakamura AJ, et al. H2AX: functional roles and potential applications. Chromosoma. 2009;118:683-692.
45. Yang SX, Nguyen D, Steinberg SM, et al. Quantitative immunohistochemical detection of gamma-H2AX in paraffin-embedded human tumor samples at National Clinical Target Validation Laboratory. ASCO Annual Meeting Proceedings. 2007;25:Abstract 10565.
46. Ji J, Redon C, Pommier Y, et al. Poly-adeninosinediphosphate-ribose polymerase inhibitors as sensitizers for therapeutic treatments in human tumor and blood mononuclear cells. ASCO Annual Meeting Proceedings. 2007;25: Abstract 14024.
47. Camidge DR, Randall KR, Foster JR, et al. Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies. Br J Cancer. 2005;92:1837-1841.
48. Fong PC, Boss DS, Carden CP, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. ASCO Annual Meeting Proceedings. 2008;26(15S):Abstract 5510.
49. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. ASCO Annual Meeting. 2009;27(15S):Abstract 5500.
50. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. ASCO Annual Meeting. 2009;27(15S):abstract CRA501.
51. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/results? term- olaparib. Accessed December 14, 2009.
52. Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose (PARP) in subjects with advanced solid tumors. ASCO Annual Meeting Proceedings. 2008;26(15S): Abstract 3577.
53. Mahany JJ, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. ASCO Annual Meeting Proceedings. 2008;26(15S):abstract 3579.
54. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/ carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. ASCO Annual Meeting. 2009;27(15S):abstract 3.
55. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.
56. O'Shaughnessy J, Osborne C, Pippen J, et al. Results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer. Presented in the Cancer Research 2009 San Antonio Breast Cancer Symposium, San Antonio, TX, 2009, abstract 3122.
57. O'Shaughnessy J, Yoffe M, Osborne C, et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. Presented in the 2008 San Antonio Breast Cancer Symposium Proceedings, San Antonio, TX, 2008, abstract 2120.
58. Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). ASCO Annual Meeting Proceedings. 2006;24(18S):abstract 8013.
59. Li J, Sha X, LoRusso PM. Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway. ASCO Annual Meeting. 2009;27(15S):abstract e14556.
60. Bedikian AY, Papadopoulos NE, Kim KB, et al. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009;27:756-763.
61. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/results? term-bsi-201. Accessed December 16, 2009.
62. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/results? term- AG014699. Accessed December 16, 2009.
63. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/results? term-abt-888. Accessed December 16, 2009.